Ceftriaxone sodium and tazobactam sodium composition

A technology of tazobactam sodium and ceftriaxone sodium, applied in the direction of active ingredients of heterocyclic compounds, antibacterial drugs, etc., can solve problems such as poor stability, increase toxic and side effects, increase pharmacological activity, and improve antibacterial effects

Inactive Publication Date: 2006-02-15
李志林
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has the characteristics of broad-spectrum, long-acting, high-efficiency, and low toxicity. It has antibacterial effects on Gram bacteria and Pseudomon

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Example

[0015] Implementation 1 One of the preparation examples of the composition of ceftriaxone sodium and tazobactam sodium

[0016] Take 2 parts (weight) of the composition of ceftriaxone sodium and tazobactam sodium and 1 part (weight) of tazobactam sodium, place them in a V-type mixer in a class 100 clean room, and mix for 5 minutes. 30-mesh sieve; put the mixed medicinal solution in the mixer and mix for 5 minutes, and then pass through a 30-mesh sieve; repeat this 3 times; put the mixed medicinal powder in a sterile tank and seal it tightly. Then check the content of intermediates in accordance with the clinical quality standards, and perform aseptic packaging after passing the test. In order to reduce the influence of residual oxygen on the content of medicines, a secondary nitrogen filling process is used in the aseptic filling process to control the oxygen content in the medicine bottle to about 1% (when nitrogen is charged once, the residual oxygen content is 5%. Around) to en...

Example Embodiment

[0017] Example 2 The second preparation example of the composition of ceftriaxone sodium and tazobactam sodium

[0018] Take 4 parts (weight) of the composition of ceftriaxone sodium and tazobactam sodium and 1 part (weight) of tazobactam sodium, place them in a V-type mixer in a class 100 clean room, and mix for 5 minutes. 30-mesh sieve; put the mixed medicinal solution in the mixer and mix for 5 minutes, and then pass through a 30-mesh sieve; repeat this 3 times; put the mixed medicinal powder in a sterile tank and seal it tightly. Then check the content of intermediates in accordance with the clinical quality standards, and perform aseptic packaging after passing the test. In order to reduce the influence of residual oxygen on the content of medicines, a secondary nitrogen filling process is used in the aseptic filling process to control the oxygen content in the medicine bottle to about 1% (when nitrogen is charged once, the residual oxygen content is 5%. Around) to ensure the...

Example Embodiment

[0019] Example 3 The third preparation example of the composition of ceftriaxone sodium and tazobactam sodium

[0020] Take 5 parts (weight) of the composition of ceftriaxone sodium and tazobactam sodium and 1 part (weight) of tazobactam sodium, place them in a V-type mixer in a class 100 clean room, and mix for 5 minutes. 30-mesh sieve; put the mixed medicinal solution in the mixer and mix for 5 minutes, and then pass through a 30-mesh sieve; repeat this 3 times; put the mixed medicinal powder in a sterile tank and seal it tightly. Then check the content of intermediates in accordance with the clinical quality standards, and perform aseptic packaging after passing the test. In order to reduce the influence of residual oxygen on the content of medicines, a secondary nitrogen filling process is used in the aseptic filling process to control the oxygen content in the medicine bottle to about 1% (when nitrogen is charged once, the residual oxygen content is 5%. Around) to ensure the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a composition of ceftriaxone sodium and tazobactam sodium, which comprises active constituents of ceftriaxone sodium and tazobactam sodium by the weight ratio of 1-10:1, preferably 2-8:1, optimally 4:1. The compound preparation can appreciably reinforce the antibiotic action to Gram-negative bacteria.

Description

technical field [0001] The invention relates to a pharmaceutical composition with broad-spectrum antibacterial effect, in particular to a composition of ceftriaxone sodium and tazobactam sodium. Background technique [0002] Ceftriaxone sodium has another name called ceftriaxone, and its trade name is roseazine. This drug is the first long-acting third-generation cephalosporin successfully developed in 1978. This product can inhibit the synthesis of mucopeptides in the process of bacterial cell wall synthesis, affect the cross-linking of peptide chains, and make cells unable to form complete cell walls and sterilize. It has the characteristics of broad-spectrum, long-acting, high-efficiency, and low toxicity. It has antibacterial effects on Gram bacteria and Pseudomonas aeruginosa resistant to multiple antibacterial drugs, but has poor stability against ESBLs produced by Gram-negative bacteria. Certain drug resistance. [0003] Bacterial drug resistance is a natural select...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/546A61P31/04A61K31/43
Inventor 李志林黄瑶蔡鹤其
Owner 李志林
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap